News

Advances in siRNA Drug Research

Review: Drug delivery systems for RNA therapeutics

Update on circRNA Vaccines

mRNA vaccine expected to prevent diseases caused by ticks

Vutrisiran, The World's Fourth RNAi Therapy, Is About to Submit A Marketing Application

From COVID-19 Vaccines to Anti-Cancer Drugs, What Is the Prospect of mRNA Therapy?

Alnylam's third RNAi therapy Lumasiran was approved by the European Union for the treatment of primary hyperoxaluria type 1 (PH1)

Breaking news: RNAi can significantly inhibit hepatitis B and is expected to become a new treatment for HBV

Competing for the last mile of vaccine research and development, mRNA vaccines become a hot spot for competition

Will the mRNA vaccine become the "savior" of COVID-19?

mRNA-1647,the first infectious disease mRNA vaccine to enter the second phase of research

First RNAi treatment for inherited rare diseases

bioRxiv.: Scientists Find siRNA drugs that may inhibit SARS-CoV-2

Cell Immunity: SARS-CoV-2 vaccines status

Onpattro, The First RNAi-based therapeutic Drug

SARS-CoV-2 is undergoing mutations. Does the vaccine still work?

Application of LC-MS in the Bioassay of Oligonucleotide Drugs

GalNAc Technology for Oligonucleotide Drug Delivery

Therapeutic siRNA: Recent Advances and Prospects

Lipids Used in COVID-19 mRNA Vaccines

Vaccine Adjuvants-CpG Oligonucleotides (CpG ODN)

First LNP-mRNA In Vivo Gene Editing Therapy Reports Positive Data

First mRNA RSV Vaccine Approved for Market Release

Bridge RNA: Third-Generation Gene Editing Tool on the Horizon

Global Influenza Vaccine Market Report: Nucleic Acid Vaccines Become Mainstream

Opus Genetics Eye Gene Therapy Receives FDA Rare Pediatric Disease Designation

Breakthrough: Novartis' siRNA Therapy Achieves Phase III Success for Atherosclerotic Cardiovascular Disease

miRNA -The 2024 Nobel Prize in Physiology or Medicine Announcement

* Only for research. Not suitable for any diagnostic or therapeutic use.
Inquiry Basket